Skepticism on the wane? Reputation study says U.S. patient groups give props to pharma

Could U.S. patient groups be warming up to pharma? Skepticism seems to be on the wane at least by some measures, according to PatientView’s annual corporate reputation study.Patient groups in the U.S. rated pharma companies’ patient-centricity, integrity and patient group partnerships much higher in this year's study, which compared 2017 to 2016. Ratings increased 10% or more in each category, while patient-centricity jumped the most last year—to 43%, up from 24% in 2016. Still, those boosts didn’t help U.S. pharma companies crack the top three among 169 U.S. patient groups polled. European and Japanese drugmakers nabbed those spots. Copenhagen-based Lundbeck was a three-peat at the top of the poll, winning the No. 1 spot for the third year in a row, followed by Brussels-based UCB and Tokyo-based Eisai. The highest-performing U.S. pharma was AbbVie in fourth place.